Cencora stock enters fiscal 2027 with stronger earnings outlook

Cencora reported stronger fiscal fourth-quarter results on Wednesday, November 4, 2026, and set a new operating framework for fiscal 2027. The company's release, summarized in an AD HOC NEWS report, showed fourth-quarter revenue up 5.5 percent year over year to 88.4 billion US dollars. Adjusted diluted earnings per share rose 21.4 percent to 4.66 US dollars.

Cencora stock traded at 300.50 euros on Lang & Schwarz at 16:06 CET on Friday, November 6, 2026. The real-time quote of Cencora stock was 5.41 percent below the 317.70-euro quote in the previous report dated November 5, 2026.

Stronger finish supports new forecast

Adjusted operating income increased 22.1 percent to 1.2 billion US dollars, while adjusted gross profit rose 23.0 percent to 3.6 billion US dollars. The adjusted operating margin expanded to 1.41 percent from 1.22 percent a year earlier.

GAAP diluted earnings per share came in at 2.71 US dollars, compared with a loss of 1.75 US dollars in the prior-year quarter. The comparison included last year's 723.9 million US dollar PharmaLex goodwill impairment charge, alongside acquisition-related costs, litigation items, tax effects and the accounting impact of the OneOncology transaction.

Fiscal 2027 priorities take shape

Management expects fiscal 2027 revenue growth of 3 to 5 percent, adjusted operating-income growth of 4 to 6 percent and adjusted diluted earnings-per-share growth of 8 to 10 percent. The earnings outlook is 19.40 to 19.75 US dollars per share, compared with 17.97 US dollars in fiscal 2026.

The company will report under Pharmaceutical Distribution and Services, Specialty Pharmaceutical and Provider Services, and Other. Specialty services are expected to deliver revenue growth of 9 to 14 percent and operating-income growth of 18 to 21 percent, ahead of the distribution business. The outlook assumes the MWI Animal Health merger with Covetrus closes on March 31, 2027.

Dividend adds to shareholder returns

Cencora declared a quarterly dividend of 0.66 US dollars per share on November 3, up from 0.60 US dollars. The payment is scheduled for November 30 to shareholders of record on November 13.

Cencora's broader market setting can be followed through the S&P 500 market overview.

More news and analyses on Cencora stock